Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CNS10-NPC-GDNF in ALS (Motor Cortex)
NCT05306457Phase 1Active, not recruiting
- Sponsor
- Cedars-Sinai Medical Center
- Start
- May 2022
- Primary completion
- Oct 2026
- Modality
- Gene Editing, Gene Silencing, Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of CNS10-NPC-GDNF in amyotrophic lateral sclerosis (ALS) (3 arms), sponsored by Cedars-Sinai Medical Center. Primary endpoints: Incidence of Adverse Events and Serious Adverse Events at 12 months and Changes from baseline in brain MRI at 12 months. Started May 2022; status: active, not recruiting.
02
Drugs
CNS10-NPC-GDNF
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT05306457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05306457.